EFG Asset Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$7.56M Buy
219,979
+12,597
+6% +$361K 0.98% 15
2025
Q2
$5.6M Buy
207,382
+7,729
+4% +$224K 0.79% 34
2025
Q1
$5.92M Sell
199,653
-6,574
-3% -$251K 0.98% 18
2024
Q4
$8.16M Buy
206,227
+1,973
+1% +$74.7K 1.11% 11
2024
Q3
$6.95M Sell
204,254
-39,624
-16% -$1.11M 1.16% 10
2024
Q2
$5.28M Sell
243,878
-13,510
-5% -$284K 0.92% 18
2024
Q1
$5.69M Buy
257,388
+27,748
+12% +$677K 0.98% 16
2023
Q4
$6.32M Sell
229,640
-197
-0.1% -$4.76K 1.2% 11
2023
Q3
$5.13M Sell
229,837
-17,855
-7% -$459K 1.22% 17
2023
Q2
$6.3M Sell
247,692
-23,080
-9% -$559K 1.35% 9
2023
Q1
$6.03M Sell
270,772
-20,556
-7% -$497K 1.33% 7
2022
Q4
$7.02M Sell
291,328
-5,205
-2% -$121K 1.58% 6
2022
Q3
$4.92M Sell
296,533
-6,823
-2% -$154K 1.14% 26
2022
Q2
$6.04M Buy
303,356
+12,153
+4% +$246K 1.27% 19
2022
Q1
$8.03M Buy
291,203
+28,823
+11% +$824K 1.2% 25
2021
Q4
$10.8M Buy
+262,380
New +$11.6M 1.41% 18

Other funds holding VCYT

EFG Asset Management's VCYT Position: Q3 2025 in Review

EFG Asset Management increased its Veracyte (VCYT) stake by 6.1% in Q3 2025, buying an estimated $361K and bringing the position to 219,979 shares worth $7.56M. The position accounts for 0.98% of the portfolio, ranked #15.

EFG Asset Management first reported a position in VCYT in Q4 2021 and has held it in 16 quarters since. The position peaked at $10.8M in Q4 2021. 298 funds tracked by Wall St. Rank hold VCYT as of Q3 2025.

  • EFG Asset Management held 219,979 shares of Veracyte worth $7.56M as of Q3 2025.
  • EFG Asset Management bought 12,597 Veracyte shares in Q3 2025, an estimated $361K.
  • Veracyte made up 0.98% of EFG Asset Management's portfolio in Q3 2025, its #15 holding.
  • EFG Asset Management first reported a position in Veracyte in Q4 2021 and has held it in 16 quarters since.
  • EFG Asset Management's Veracyte position peaked at $10.8M in Q4 2021.
  • 298 funds tracked by Wall St. Rank held Veracyte as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.